Warfarin Poisoning with Delayed Rebound Toxicity
Overview
Affiliations
Background: Intentional poisoning with warfarin is not the same as over-anticoagulation, for which guidelines exist. The coagulopathy resulting from a warfarin overdose is reversed with vitamin K, the dose and timing of which is often guided by experience with the management of over-anticoagulation with warfarin therapy, rather than acute overdose.
Case Report: We report a case of a 50-year-old man who ingested an unknown amount of his warfarin, venlafaxine, and paracetamol. He presented with an international normalized ratio (INR) of 2.5, which steadily increased over 24 h to 7, despite receiving an initial 1 mg of vitamin K. He was then treated with 5 mg vitamin K, and once the INR returned to 4.5, 40 h post ingestion, he was discharged home. He was also treated with a full course of acetylcysteine for the paracetamol overdose. The following day his INR rebounded to 8.5 and he suffered a spontaneous epistaxis requiring readmission; he was treated with low titrated doses of vitamin K. The warfarin concentration was 74.6 μg/mL 26 h post ingestion and decreased to 3.7 μg/mL over 72 h. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Our case highlights the risk of a rebound elevated INR even 3 days after acute warfarin overdose despite treatment with vitamin K. Understanding the pharmacokinetics of vitamin K in comparison with warfarin, repeat INR testing, and continued treatment with oral vitamin K may help avoid complications of rebound coagulopathy in warfarin overdose.
Omoto R, Umemura Y, Kokubu Y, Kiguchi T, Fujimi S Acute Med Surg. 2025; 12(1):e70036.
PMID: 39790712 PMC: 11712172. DOI: 10.1002/ams2.70036.
Warfarin Overdose in an Adolescent Not Dependent on Anticoagulation: Reversal Strategy and Kinetics.
Watson C, Simpson M, Whitledge J, Patterson A, Burns M J Med Toxicol. 2022; 18(4):334-339.
PMID: 36066724 PMC: 9492822. DOI: 10.1007/s13181-022-00907-1.
Unintentional ingestion of a high dose of acenocoumarol in a young child.
Brands M, Sytema J, van Hulst M, Kamps A BMJ Case Rep. 2021; 14(4).
PMID: 33795273 PMC: 8023619. DOI: 10.1136/bcr-2020-240365.
Parkin S, Neale J, Brown C, Campbell A, Castillo F, Jones J Int J Drug Policy. 2020; 79:102751.
PMID: 32304981 PMC: 7572435. DOI: 10.1016/j.drugpo.2020.102751.